Advancing Life-Changing Discoveries in Neuroscience Neurocrine Biosciences (Nasdaq: NBIX) Q1 2025 Earnings Presentation May 5,2025 Safe Harbor and Forward-Looking Statements In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our products and product candidates; the value our products and/or our product candidates may br ...

Neurocrine Biosciences (NBIX) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Company Participants Todd Tushla - VP, IRKyle Gano - CEOMatt Abernethy - Chief Financial OfficerEric Benevich - Chief Commercial OfficerEiry Roberts - Chief Medical OfficerPaul Matteis - Managing Director, Head of Therapeutics ResearchPhoebe Tan - Senior Biotechnology Equity Research AssociateTazeen Ahmad - MD - US Equity ResearchPhilip Nadeau - MD, Health Care – BiotechnologyBrian Abrahams - MD & Global Sector Head - Health Care R ...

Neurocrine Biosciences (NBIX) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Speaker0 Good day, everyone, and welcome to Neurocrine Biosciences Reports First Quarter twenty twenty five Results. At this time, all participants are in a listen only mode. Later, you will have the opportunity to ask questions during the question and answer session. Please note, today's call will be recorded, and I will be standing by should you need any assistance. It is now my pleasure to turn the conference over to Todd Tuchla ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 6027 Edgewood Bend Court For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the ...

Sales Performance - INGREZZA (valbenazine) first-quarter 2025 net product sales reached $545 million, an 8% increase compared to the first quarter of 2024[5] - CRENESSITY (crinecerfont) first-quarter 2025 net product sales were $14.5 million, with 413 total patient enrollment start forms indicating strong initial demand[5] - The company reaffirms 2025 net product sales guidance for INGREZZA in the range of $2.5 billion to $2.6 billion[2] - Total revenues for the first quarter of 2025 were $572.6 million, compared to $515.3 million in the first quarter of 2024[6] - Total revenues for the three months ended March 31, 2025, were $572.6 million, a 11.1% increase from $515.3 million in the same period of 2024[18] - Net product sales increased to $563.7 million, up 10.7% from $509.0 million year-over-year[18] Income and Earnings - GAAP net income for the first quarter of 2025 was $7.9 million, down from $43 million in the same period of 2024[9] - Non-GAAP net income for the first quarter of 2025 was $71.5 million, compared to $124.8 million in the first quarter of 2024[9] - Operating income decreased to $23.6 million, down 76.2% from $99.3 million in the same quarter of 2024[18] - Net income for the quarter was $7.9 million, a decline of 81.8% from $43.4 million in the previous year[18] - Non-GAAP net income was reported at $71.5 million, down 42.7% from $124.8 million in the same quarter of 2024[22] - Diluted earnings per share (EPS) on a GAAP basis was $0.08, compared to $0.42 in the prior year, reflecting an 81.0% decrease[22] Research and Development - The company initiated Phase 3 registrational programs for osavampator in major depressive disorder and NBI-'568 in schizophrenia[7] - Research and development expenses rose significantly to $263.2 million, a 65.1% increase compared to $159.4 million in the prior year[18] - The company plans to invest $960 million to $1.010 billion in GAAP R&D expenses for the full year 2025[10] Financial Position - The company has approximately $1.8 billion in cash, cash equivalents, and marketable securities as of March 31, 2025[9] - Cash, cash equivalents, and marketable securities totaled $943.5 million as of March 31, 2025, down from $1,076.1 million at the end of 2024[20] - Total assets decreased to $3,687.7 million from $3,718.7 million at the end of 2024[20] - Stockholders' equity declined to $2,535.7 million, down from $2,589.7 million at the end of the previous year[20] Share Repurchase - A second share repurchase program was announced to repurchase up to $500 million of outstanding common stock, with $150 million already repurchased as of March 31, 2025[9]

INGREZZA® (valbenazine) First-Quarter 2025 Net Product Sales of $545 Million and Reaffirms 2025 Net Product Sales Guidance of $2.5 - $2.6 BillionCRENESSITYTM (crinecerfont) First-Quarter 2025 Net Product Sales of $14.5 Million with 413 Total Patient Enrollment Start FormsInitiated Phase 3 Registrational Programs for Osavampator in Major Depressive Disorder and NBI-'568 in Schizophrenia to Position for Next Phase of Growth SAN DIEGO, May 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) tod ...

-- Majority of individuals polled reported tardive dyskinesia negatively impacts their day-to-day ability to function, including individuals living with mild or moderate uncontrolled movements1 SAN DIEGO, May 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the release of findings from a new survey conducted by The Harris Poll highlighting the profound negative impact of tardive dyskinesia on patients and reinforcing the need for routine screening, earlier diagnosis and tr ...

NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with NeurocrineFor more information, please read Neurocrine’s announcement (link) Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has initiated a Phase 3 registrational program to evaluate the efficacy, safety and toler ...

SAN DIEGO, April 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational program to evaluate the efficacy, safety and tolerability of NBI-1117568, the company's investigational oral muscarinic M4 selective orthosteric agonist, as a potential treatment for schizophrenia. Positive top-line data for the Phase 2 clinical study in adults with schizophrenia were reported in August 2024."There is a significant need for new and innovative medic ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...